• In March 2022, Eurofins Genomics supported the mission of 'Our Future Health,' the UK's largest-ever health analysis program. The initiative aims to genotype five million individuals to create a comprehensive understanding of the health of the UK's population. This data is valuable for diagnosing, preventing, and treating various ailments.

• In June 2022, Centogene NV announced an expansion of its collaboration with Agios Pharmaceuticals Inc. to develop improved therapeutics for genetically confirmed diseases using PYRUKYND. PYRUKYND is the first-in-class, selective, small-molecule activator of pyruvate kinase enzymes.

• In February 2021, Hydroxycut released its novel product, CUT Energy, a delicious, clean energy drink. This potent blend was carefully formulated for regular energy drink consumers, exercise enthusiasts, and dieters looking to lose weight.

In this report, the Global Gene Panel Market has been segmented by Product and Services, Techniques, Design, Application, End User and Geography.

Global Gene Panel Market, Segmentation by Product and Services

The Global Gene Panel Market has been segmented by Product and Services into Test Kits and Testing Services.

Test Kits
Test kits are gaining traction in the gene panel market for their ease of use, affordability, and fast turnaround times. Frequently used for detecting hereditary conditions and cancer-associated mutations, they represent approximately 42% of the market. Their growth is further driven by consumer interest in at-home testing and innovations in genetic assay technology.

Testing Services
Testing services dominate the product and services segment with a substantial 58% share, thanks to their clinical reliability, detailed reporting, and integration with healthcare providers. These services support advanced diagnostic accuracy, making them essential in the movement toward personalized treatment plans. Rising awareness and trust in professional genetic analysis continue to propel their adoption.

Global Gene Panel Market, Segmentation by Techniques

The Global Gene Panel Market has been segmented by Techniques into Amplicon Based Approach and Hybridization Based Approach.

Amplicon Based Approach
The amplicon based approach remains a popular method in gene panel testing, especially valued for its cost-efficiency, high sensitivity, and suitability for detecting known genetic mutations. Often applied in cancer screening and rare disease diagnostics, this technique holds about 45% of the market. Its ability to work with minimal and degraded DNA samples makes it ideal for clinical and lab settings focused on rapid, targeted sequencing.

Hybridization Based Approach
Commanding approximately 55% of the gene panel market, the hybridization based approach is known for its broad variant detection capabilities and deep sequencing accuracy. This method supports both known and novel mutation identification, making it a top choice for complex genomic studies. It plays a vital role in personalized medicine and exome-scale research due to its comprehensive coverage and versatility.

Global Gene Panel Market, Segmentation by Design

The Global Gene Panel Market has been segmented by Design into Predesigned Gene Panel and Customized Gene Panel.

Predesigned Gene Panel
Predesigned gene panels are widely used for their clinical reliability, standardized design, and quick deployment in diagnostic workflows. These panels are expertly curated to cover common genetic mutations and currently capture about 63% of the market. Their growing popularity stems from their ease of use and suitability for high-throughput clinical applications targeting known disease genes.

Customized Gene Panel
Customized gene panels provide flexibility and precision, catering to specific research or diagnostic goals. Representing around 37% of the global market, these panels are particularly favored in studies involving rare diseases, novel mutations, or niche medical applications. Their tailored approach is central to advancing personalized medicine and innovative genomic research.

Global Gene Panel Market, Segmentation by Application

The Global Gene Panel Market has been segmented by Application into Cancer Risk Assessment, Pharmacogenetics, Diagnosis of Congential Disorders, and Others.

Cancer Risk Assessment
Cancer risk assessment is the most prominent application of gene panels, representing nearly 49% of the market. These panels are crucial for detecting hereditary cancer mutations, enabling early diagnosis and prevention strategies. Their growing use in clinical genomics is accelerating personalized treatment plans and reducing long-term healthcare costs.

Pharmacogenetics
Pharmacogenetics accounts for around 23% of the gene panel market, focusing on how genes influence drug response. This approach allows for individualized treatment plans, reduces adverse effects, and increases drug efficacy across therapeutic areas like oncology and psychiatry. Its role is rapidly expanding with the rise of precision medicine.

Diagnosis of Congenital Disorders
Diagnosis of congenital disorders makes up approximately 18% of the market, where gene panels help identify inherited genetic abnormalities early in life. These diagnostics enhance the accuracy and speed of detecting disorders such as cystic fibrosis and Tay-Sachs, enabling timely interventions and improved outcomes.

Others
Others account for nearly 10% of the market and cover emerging applications like rare disease research, neurological evaluations, and infectious disease genomics. This segment reflects the expanding utility of gene panels in diverse medical and scientific fields, paving the way for next-generation diagnostic innovations.

Global Gene Panel Market, Segmentation by End User

The Global Gene Panel Market has been segmented by End User into Hospitals, Diagnostic Laboratories, Pharmaceutical Companies and Others.

Hospitals
Hospitals lead the gene panel market with about 38% of total usage, driven by the growing incorporation of genomic testing into patient care. These institutions rely on gene panels for diagnosis, treatment guidance, and personalized healthcare strategies, making them central to the clinical application of genomics.

Diagnostic Laboratories
Diagnostic laboratories account for roughly 34% of the market, offering high-throughput and accurate genetic testing. Equipped with cutting-edge technology and expert staff, these labs play a key role in enabling fast and reliable disease diagnosis through gene panel analysis.

Pharmaceutical Companies
Pharmaceutical companies represent about 18% of end-user adoption, using gene panels in drug development, biomarker research, and clinical trials. Their focus on precision therapies and genotype-based drug responses is driving sustained demand in this segment.

Others
Others, contributing around 10%, include academic centers, biotech startups, and contract research organizations. These groups use gene panels for innovative research, new assay development, and exploring the frontiers of genomic science in diverse health applications.

Global Gene Panel Market, Segmentation by Geography

In this report, the Global Gene Panel Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Gene Panel Market Share (%), by Geographical Region, 2024

North America
North America leads the global gene panel market with a commanding 45% share, thanks to its advanced medical infrastructure, strong focus on personalized medicine, and active biotechnology sector. High funding in genomics and favorable regulatory frameworks also accelerate the region’s adoption of gene panel technologies.

Europe
Europe accounts for approximately 25% of the market, driven by robust genetic research programs, public healthcare integration, and reimbursement policies for genomic testing. Nations like the UK, Germany, and France are spearheading the use of gene panels in both clinical and research settings.

Asia Pacific
Asia Pacific holds about 18% of the gene panel market and is experiencing rapid growth due to expanding healthcare access, government-supported genomics initiatives, and a large untapped patient population. Key markets include China, India, and Japan, where precision medicine is gaining momentum.

Middle East and Africa
Middle East and Africa contribute roughly 7% to the global gene panel market. The region’s growth is supported by improved diagnostic infrastructure, rising awareness of inherited diseases, and strategic investments in healthcare innovation in countries like the UAE and South Africa.

Latin America
Latin America makes up around 5% of the gene panel market, led by Brazil, Mexico, and Argentina. Growing acceptance of genomic diagnostics, gradual healthcare system reforms, and regional precision medicine initiatives are fostering the adoption of gene panel technologies.